Apremilast in psoriasis: The PSOR-003 (Double-Blind, Randomized, Placebo-Controlled Comparison of CC10004 in Subjects With Moderate to Severe Plaque Type Psoriasis; NCT00606450) study
Double-blind, randomized, placebo-controlled comparison of CC10004 in subjects with moderate to severe plaque type psoriasis (PSOR-003) (NCT00606450)